Skip to main content

Table 1 Comparison of clinicopathologic features of EGC among different locations

From: Distinct clinicopathological differences between early gastric cardiac and non-cardiac carcinomas: a single-center retrospective study of 329 radical resection cases

Clinicopathologic factor Tumor location p value
  Cardia Fundus–corpus Antrum–angularis–pylorus Non-cardia Total  
Number 70 (21.9) 78 (24.5) 181 (56.7) 259 (78.1) 329 NS
Gender       
 Male 50 (71.4) 53 (67.9) 121 (66.9) 174 (67.2) 224 (68.1) NS
 Female 20 (28.6) 25 (32.1) 60 (33.1) 85 (32.8) 105 (31.9)  
 M/F ratio 2.50 2.12 2.02 2.05 2.13  
Age (year)       
 ≤ 40 0 (0.0) 2 (2.6) 12 (6.6) 14 (5.4) 14 (4.3) NS
 41–69 54 (77.1) 62 (79.5) 139 (76.8) 201 (77.6) 255 (77.5)  
 ≥ 70 16 (22.9) 14 (18.0) 30 (16.6) 44 (17.0) 60 (18.2)  
 Average (SD) 64.33 ± 7.14 60.77 ± 10.18 58.26 ± 11.94 59.01 ± 11.48 60.15 ± 10.91 < 0.01
Macroscopic feature       
 I 5 (7.1) 1 (1.3) 8 (4.4) 9 (3.5) 14 (4.3) < 0.05
 IIa 2 (2.9) 2 (2.6) 8 (4.4) 10 (3.9) 12 (3.6)  
 IIb 16 (22.9) 14 (17.9) 18 (9.9) 32 (12.4) 48 (14.6)  
 IIc 23 (32.9) 24 (30.8) 58 (32.0) 82 (31.7) 105 (31.9)  
 III 24 (34.3) 37 (47.4) 89 (49.2) 126 (48.6) 150 (45.6)  
 I + IIa 7 (10.0) 3 (3.8) 16 (8.8) 19 (7.3) 26 (7.9) < 0.05
 IIb 16 (22.9) 14 (17.9) 18 (9.9) 32 (12.4) 48 (14.6)  
 IIc + III 47 (67.1) 61 (78.2) 147 (81.2) 208 (80.3) 255 (77.5)  
Size (cm)       
 ≤ 0.9 11 (15.7) 15 (19.2) 34 (18.8) 49 (18.9) 60 (18.2) NS
 1–1.9 27 (38.6) 27 (34.6) 59 (32.6) 86 (33.2) 113 (34.3)  
 2–2.9 20 (28.6) 21 (26.9) 51 (28.2) 72 (27.8) 92 (28.0)  
 > 3 12 (17.1) 15 (19.2) 37 (20.4) 52 (20.1) 64 (19.5)  
Invasion depth       
 M2 9 (12.9) 17 (21.8) 42 (23.2) 59 (22.8) 68 (20.7) NS
 M3 19 (27.1) 19 (24.4) 52 (28.8) 71 (27.4) 90 (27.4)  
 SM1 10 (14.3) 10 (12.8) 23 (12.7) 33 (12.7) 43 (13.1)  
 SM2 32 (45.7) 32 (41.0) 64 (35.4) 96 (37.1) 128 (38.9)  
Histology type       
 Tubular adenocarcinoma 40 (57.1) 42 (53.8) 81 (44.8) 123 (47.5) 163 (49.5) < 0.01
 Papillary adenocarcinoma 13 (18.6) 2 (2.6) 11 (6.1) 13 (5.0) 26 (7.9)  
 Micropapillary adenocarcinoma 1 (1.4) 1 (1.3) 2 (1.1) 3 (1.2) 4 (1.2)  
 Poorly cohesive carcinoma 2 (2.9) 14 (17.9) 32 (17.7) 46 (17.8) 48 (14.6)  
 Mucinous carcinoma 1 (1.4) 2 (2.6) 1 (0.6) 3 (1.2) 4 (1.2)  
 Mixed PCC and adenocarcinoma 6 (8.6) 15 (19.2) 45 (24.9) 60 (23.2) 66 (20.1)  
 Mixed mucinous and tubular adenocarcinoma 3 (4.3) 1 (1.3) 5 (2.8) 6 (2.3) 9 (2.7)  
 Others (neuroendocrine/medullary/adenosqumous carcinoma) 4 (5.7) 1 (1.3) 4 (2.2) 5 (1.9) 9 (2.7)  
Differentiation       
 Well 17 (24.3) 9 (11.5) 17 (9.4) 26 (10.0) 43 (13.1)  < 0.05
 Moderate 42 (60.0) 37 (47.4) 83 (45.9) 120 (46.3) 162 (49.2)  
 Poorly 11 (15.7) 32 (41.0) 81 (44.8) 113 (43.6) 124 (37.7)  
Lymphovascular invasion       
 Absence 59 (84.3) 69 (88.5) 149 (82.3) 218 (84.2) 277 (84.2) NS
 Presence 11 (15.7) 9 (11.5) 32 (17.7) 41 (15.8) 52 (15.8)  
Perineural invasion       
 Absence 67 (95.7) 76 (97.4) 172 (95.0) 248 (95.8) 315 (95.7) NS
 Presence 3 (4.3) 2 (2.6) 9 (5.0) 11 (4.2) 14 (4.3)  
HP       
 Absence 52 (74.3) 49 (62.8) 131 (72.4) 180 (69.5) 232 (70.5) NS
 Presence 18 (25.7) 29 (37.2) 50 (27.6) 79 (30.5) 97 (29.5)  
LNM       
 Absence 63 (90.0) 66 (84.6) 151 (83.4) 217 (83.8) 280 (85.1) NS
 Presence 7 (10.0) 12 (15.4) 30 (16.6) 42 (16.2) 49 (14.9)  
 N1 5 (7.1) 6 (7.7) 13 (7.2) 19 (7.3) 24 (7.3)  
 N2 1 (1.4) 5 (6.4) 11 (6.1) 16 (6.2) 17 (5.2)  
 N3 1 (1.4) 1 (1.3) 6 (3.3) 7 (2.7) 8 (2.4)  
  1. SD standard deviation, PCC poorly cohesive carcinoma, NS not significant
\